United States · FDA National Drug Code directory
Ondansetron
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 51655-913_4a8dd8e9-dd5c-efb4-e063-6294a90a89d9
- Product NDC
- 51655-913
- Form
- TABLET, ORALLY DISINTEGRATING
- Composition / generic term
- Ondansetron
- Labeler
- Northwind Health Company, LLC
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20210122
- Source listing expiry
- 20271231
Source-listed ingredients
- ONDANSETRON — 4 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 20 TABLET, ORALLY DISINTEGRATING in 1 BAG (51655-913-20) · 51655-913-20
- 10 TABLET, ORALLY DISINTEGRATING in 1 BAG (51655-913-53) · 51655-913-53
- 15 TABLET, ORALLY DISINTEGRATING in 1 BAG (51655-913-54) · 51655-913-54
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →